PDS Biotechnology Corp (STU:EU6)

Q3 2025 PDS Biotechnology Corp Earnings Call Transcript

Nov 13, 2025 / 01:00 PM GMT

Release Date Price: €0.822 (-2.20%)

Transcript 10-Q8-K8-K

Key Points

Positve

PDS Biotechnology Corp (PDSB) announced the completion of the Versatile 002 trial, showing a median overall survival of 39.3 months in patients with HPV-16 positive head and neck cancer.
The company plans to amend the Versatile 003 trial to include progression-free survival as a primary endpoint, potentially accelerating regulatory submission.
PDS Biotechnology Corp (PDSB) reported a decrease in net loss for Q3 2025, primarily due to lower operating expenses.
The National Cancer Institute presented new clinical data at the 2025 Society for Immunotherapy of Cancer meeting, highlighting the effectiveness of PDSB's immunotherapy platforms.
PDS Biotechnology Corp (PDSB) has strong collaborations with leading institutions like the National Cancer Institute, MD Anderson Cancer Center, and the Mayo Clinic, aiding in the development of their pipeline.

Negative

PDS Biotechnology Corp (PDSB) reported a net loss of $9 million for Q3 2025, although this was an improvement from the previous year.
The company's cash balance decreased significantly from $41.7 million at the beginning of the year to $26.2 million as of September 30, 2025.
There is a temporary pause in the Versatile 003 trial as the company seeks to amend the trial protocol, which could delay progress.
The company has not yet disclosed the new sample size for the Versatile 003 trial, pending discussions with the FDA.
PDS Biotechnology Corp (PDSB) faces challenges in the head and neck cancer space, with significant strategic interest and competition from other therapies targeting HPV-negative patients.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PDSB.OQ - PDS Biotechnology Corp
Q3 2025 PDS Biotechnology Corp Earnings Call
Nov 13, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings. Welcome to the PDS Biotech's 3rd quarter 2025 earnings conference call. At this time, all participants are in listen-only mode.

A question-and-answer session will follow the formal presentation.

If anyone should require operator assistance during the conference, please press 0 on your telephone keypad.

Please note this conference is being recorded.

At this time we'll turn the conference over to Tom Johnson with Lifesize Advisors. Tom, you may now begin.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.